Blueshift Asset Management’s Quest Diagnostics DGX Stock Holding History

Blueshift Asset Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.59M	Buy	12,228 +10,647	+673%	+$2.09M	0.6%	8
2026 Q1	$310K	Sell	1,581 -3,966	-71%	-$771K	0.09%	334
2025 Q4	$963K	Buy	5,547 +2,374	+75%	+$432K	0.28%	85
2025 Q3	$605K	Sell	3,173 -367	-10%	-$65.1K	0.19%	156
2025 Q2	$636K	Sell	3,540 -6,105	-63%	-$1.06M	0.2%	139
2025 Q1	$1.63M	Buy	+9,645	New	+$1.58M	0.65%	22
2022 Q4	–	Sell	-35,611	Closed	-$4.37M	–	413
2022 Q3	$4.37M	Sell	35,611 -15,165	-30%	-$2M	0.93%	8
2022 Q2	$6.75M	Buy	50,776 +51	+0.1%	+$6.95K	1.11%	3
2022 Q1	$6.94M	Buy	50,725 +19,280	+61%	+$2.69M	0.63%	23
2021 Q4	$5.44M	Buy	+31,445	New	+$4.78M	0.48%	42
2021 Q3	–	Sell	-7,936	Closed	-$1.05M	–	1062
2021 Q2	$1.05M	Sell	7,936 -217	-3%	-$28.4K	0.06%	344
2021 Q1	$1.05M	Buy	8,153 +6,097	+297%	+$751K	0.11%	269
2020 Q4	$245K	Buy	+2,056	New	+$251K	0.03%	571
2020 Q3	–	Sell	-9,729	Closed	-$1.11M	–	634
2020 Q2	$1.11M	Buy	+9,729	New	+$1.03M	0.18%	166

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Blueshift Asset Management's DGX Position: Q2 2026 in Review

Blueshift Asset Management increased its Quest Diagnostics (DGX) stake by 673% in Q2 2026, buying an estimated $2.09M and bringing the position to 12,228 shares worth $2.59M. The position accounts for 0.6% of the portfolio, ranked #8.

Blueshift Asset Management first reported a position in DGX in Q2 2020 and has held it in 14 quarters since. The position peaked at $6.94M in Q1 2022. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Blueshift Asset Management held 12,228 shares of Quest Diagnostics worth $2.59M as of Q2 2026.
Blueshift Asset Management bought 10,647 Quest Diagnostics shares in Q2 2026, an estimated $2.09M.
Quest Diagnostics made up 0.6% of Blueshift Asset Management's portfolio in Q2 2026, its #8 holding.
Blueshift Asset Management first reported a position in Quest Diagnostics in Q2 2020 and has held it in 14 quarters since.
Blueshift Asset Management's Quest Diagnostics position peaked at $6.94M in Q1 2022.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.